nortriptyline - CAS 72-69-5
Catalog number:
72-69-5
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C19H21N
Molecular Weight:
263.38
COA:
Inquire
Targets:
Others
Description:
Nortriptyline is a second-generation antidepressant originated by Lilly. It is a non-selective monoamine reuptake inhibitor. Nortriptyline can be used for the treatment of major depression and childhood nocturnal enuresis.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Powder
Synonyms:
10,11-dihydro-5-(3-methylaminopropylidene)-5h-dibenzo[a,d][1,4]cycloheptene;10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptane-delta,gamma-propylamine;10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamin;10,11-dihydro-n-methyl-5h-;894-71-3(hydrochloride)
Solubility:
Soluble in DMSO
Storage:
-20℃ Freezer
MSDS:
Inquire
Application:
major depression;childhood nocturnal enuresis
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
Density:
1.084 g/cm3
InChIKey:
PHVGLTMQBUFIQQ-UHFFFAOYSA-N
InChI:
1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
Canonical SMILES:
C1(\c2c(CCc3c1cccc3)cccc2)=C\CCNC
Current Developer:
Originator Lilly
1.Is increased antidepressant exposure a contributory factor to the obesity pandemic?
Lee SH1, Paz-Filho G1, Mastronardi C1, Licinio J2, Wong ML2. Transl Psychiatry. 2016 Mar 15;6:e759. doi: 10.1038/tp.2016.25.
Major depressive disorder (MDD) and obesity are both common heterogeneous disorders with complex aetiology, with a major impact on public health. Antidepressant prescribing has risen nearly 400% since 1988, according to data from the Centers for Disease Control and Prevention (CDC). In parallel, adult obesity rates have doubled since 1980, from 15 to 30 percent, while childhood obesity rates have more than tripled. Rising obesity rates have significant health consequences, contributing to increased rates of more than thirty serious diseases. Despite the concomitant rise of antidepressant use and of the obesity rates in Western societies, the association between the two, as well as the mechanisms underlying antidepressant-induced weight gain, remain under explored. In this review, we highlight the complex relationship between antidepressant use, MDD and weight gain. Clinical findings have suggested that obesity may increase the risk of developing MDD, and vice versa.
2.Combined pharmacotherapy and behavioural interventions for smoking cessation.
Stead LF1, Koilpillai P, Fanshawe TR, Lancaster T. Cochrane Database Syst Rev. 2016 Mar 24;3:CD008286. doi: 10.1002/14651858.CD008286.pub3.
BACKGROUND: Both behavioural support (including brief advice and counselling) and pharmacotherapies (including nicotine replacement therapy (NRT), varenicline and bupropion) are effective in helping people to stop smoking. Combining both treatment approaches is recommended where possible, but the size of the treatment effect with different combinations and in different settings and populations is unclear.
3.Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
Lee H1, Kang S1, Kim W1. PLoS One. 2016 Mar 8;11(3):e0150460. doi: 10.1371/journal.pone.0150460. eCollection 2016.
An in silico chemical genomics approach is developed to predict drug repositioning (DR) candidates for three types of cancer: glioblastoma, lung cancer, and breast cancer. It is based on a recent large-scale dataset of ~20,000 drug-induced expression profiles in multiple cancer cell lines, which provides i) a global impact of transcriptional perturbation of both known targets and unknown off-targets, and ii) rich information on drug's mode-of-action. First, the drug-induced expression profile is shown more effective than other information, such as the drug structure or known target, using multiple HTS datasets as unbiased benchmarks. Particularly, the utility of our method was robustly demonstrated in identifying novel DR candidates. Second, we predicted 14 high-scoring DR candidates solely based on expression signatures. Eight of the fourteen drugs showed significant anti-proliferative activity against glioblastoma; i.e., ivermectin, trifluridine, astemizole, amlodipine, maprotiline, apomorphine, mometasone, and nortriptyline.
4.Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.
Lauterbach EC1. Am J Neurodegener Dis. 2016 Mar 1;5(1):29-51. eCollection 2016.
Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of neurodegeneration in MCI and early PD via inflammatory mechanisms and the generation of degenerative proinflammatory cytokines. Psychiatric disorders, prevalent in AD and PD, are often treated with psychiatric drugs (psychotropics), raising the question of whether psychotropics might therapeutically affect microglial activation, MCI, and PD. The literature of common psychotropics used in treating psychiatric disorders was reviewed for preclinical and clinical findings regarding microglial activation. Findings potentially compatible with reduced microglial activation or reduced microglial inflammogen release were evident for: antipsychotics including neuroleptics (chlorpromazine, thioridazine, loxapine) and atypicals (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone); mood stabilizers (carbamazepine, valproate, lithium); antidepressants including tricyclics (amitriptyline, clomipramine, imipramine, nortriptyline), SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), venlafaxine, and bupropion; benzodiazepine anxiolytics (clonazepam, diazepam); cognitive enhancers (donepezil, galantamine, memantine); and other drugs (dextromethorphan, quinidine, amantadine).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


Marinopyrrole A
(CAS: 1010732-14-5)

Marinopyrrole A is a small molecule Mcl-1 inhibitor. It could induce Mcl-1 proteasomal degradation without transcriptional downregulation. It has the potential ...

CMPD101
(CAS: 865608-11-3)

CMPD101 is a selective GRK2/3 inhibitor with IC50 value is 54 nM for GRK3 and 32 nM for GRK2. It shows selectivity for GRK2/3 over GRK1/5. It can also reduce DA...

CAS 126054-77-1 Atractyloside A

Atractyloside A
(CAS: 126054-77-1)

Atractyloside A(126054-77-1) is a natural TCM reference compound.

CAS 1227633-49-9 SR-1

SR-1
(CAS: 1227633-49-9)

NCT-501
(CAS: 1802088-50-1)

NCT-501 is a potent and selective inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) with IC50 of 40 nM.

CAS 4312-32-7 (R,S)-Stylopine

(R,S)-Stylopine
(CAS: 4312-32-7)

Extract from the plant of Argemone mexicana acts as an important intermediate in the biosynthesis of benzophenanthridine alkaloids, such as Sanguinarine.

CAS 57378-72-0 Isochlorogenic acid C

Isochlorogenic acid C
(CAS: 57378-72-0)

Source from The herbs of Laggera alata, Isochlorogenic acid C is a selective inhibitor of human immunodeficiency virus type 1 integrase.

CAS 7432-28-2 Schisandrin

Schisandrin
(CAS: 7432-28-2)

Schisandrin has various therapeutic effects on a range of medical conditions such as anti-asthmatic, anti-cancer, and anti-inflammatory effects.

CAS 1800025-30-2 MGAT2-IN-1

MGAT2-IN-1
(CAS: 1800025-30-2)

An orally active inhibitor of monoacylglycerol acyltransferase (MGAT2) (IC50= 7.8 for human, and 2.4 nM for mouse MGAT2).

CAS 55-06-1 Liothyronine Sodium

Liothyronine Sodium
(CAS: 55-06-1)

Liothyronine Sodium is the most potent form of thyroid hormone acting on the body to increase the basal metabolic rate, affect protein synthesis.

CAS 1046045-61-7 FGH10019

FGH10019
(CAS: 1046045-61-7)

FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC50 of 1 μM, 5-10 times lower than the IC50 of fatostatin (~10 μM).

(2R,βR)-GC376

The impurity of GC376 and a 3CLpro inhibitor

CAS 58749-22-7 Licochalcone A

Licochalcone A
(CAS: 58749-22-7)

Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.

CAS 28598-08-5 Cinoctramide

Cinoctramide
(CAS: 28598-08-5)

Cinoctramide is an intermediate of pharmaceutical synthesis.

BMS-394136
(CAS: 343246-73-1)

BMS-394136 is a synthetic bio-active chemical.

Nicodicosapent
(CAS: 1269181-69-2)

Nicodicosapent is a bio-active molecular as an antihypertrigylceridemic drug candidate.

CAS 31677-93-7 Bupropion hydrochloride

Bupropion hydrochloride
(CAS: 31677-93-7)

Amfebutamone (Bupropion) HCl is a selective norepinephrine-dopamine reuptake inhibitor with IC50 of 6.5 and 3.4μM for the reuptake of dopamine and norepinephrin...

CI 986
(CAS: 130116-16-4)

CI 986 is a nonulcerogenic anti-inflammatory agent as a Arachidonic acid inhibitor originated by Pfizer. In 1994, Preclinical for Inflammation was discontinued.

CAS 175135-47-4 O4I1

O4I1
(CAS: 175135-47-4)

O4I1 is a potent inducer of Oct3/4. O4I1 enhanced Oct3/4 expression. O4I1 not only promoted expression and stabilization of Oct3/4 but also enhanced its transcr...

T7 Tag Peptide

T7 Tag Peptide, an epitope tag composed of an 11-residue peptide encoded from the leader sequence of the T7 bacteriophage gene10, and serves as a tag in many ex...

Chemical Structure

CAS 72-69-5 nortriptyline

Quick Inquiry

Verification code

Featured Items